Prelude Therapeutics Inc Cash Flow Conversion Efficiency
Prelude Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Prelude Therapeutics Inc (PRLD) has a cash flow conversion efficiency ratio of -0.327x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.11 Million) by net assets ($58.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Prelude Therapeutics Inc (2018–2024)
Cash flow conversion efficiency of Prelude Therapeutics Inc from 2018 to 2024. This chart illustrates how Prelude Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Prelude Therapeutics Inc for real-time trading data and today's change.
Prelude Therapeutics Inc Cash Flow Conversion Ratio Explained
Prelude Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Prelude Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prelude Therapeutics Inc ranked by their cash flow conversion efficiency. Also see PRLD market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Etga Group Ltd
TA:ETGA
|
-0.498x |
|
CSG Holding Co Ltd
SHE:200012
|
0.023x |
|
GEVORKYAN as
PR:GEV
|
N/A |
|
ST.GEORGE MINING LTD
F:S0G
|
N/A |
|
Sea Sonic Electronics Co Ltd
TWO:6203
|
0.030x |
|
Affinity Bancshares Inc
NASDAQ:AFBI
|
0.034x |
|
D-Box Technologies Inc.
TO:DBO
|
0.058x |
|
Wellcall Holdings Bhd
KLSE:7231
|
0.095x |
Annual Cash Flow Conversion Efficiency for Prelude Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Prelude Therapeutics Inc from 2018 to 2024. Review Prelude Therapeutics Inc (PRLD) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $131.46 Million | $-102.89 Million | -0.783x | -73.32% |
| 2023-12-31 | $237.09 Million | $-107.06 Million | -0.452x | -5.40% |
| 2022-12-31 | $195.44 Million | $-83.73 Million | -0.428x | -46.63% |
| 2021-12-31 | $285.90 Million | $-83.53 Million | -0.292x | -34.25% |
| 2020-12-31 | $212.18 Million | $-46.18 Million | -0.218x | -141.90% |
| 2019-12-31 | $-49.41 Million | $-25.66 Million | 0.519x | -9.01% |
| 2018-12-31 | $-22.69 Million | $-12.95 Million | 0.571x | -- |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more